MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue Growth

Rhea-AI Summary

Mangoceuticals, Inc. (NASDAQ: MGRX) launches a direct-to-clinics sales division, allowing doctors to prescribe MangoRx products from their offices. The company aims to increase recurring revenues and reduce customer acquisition costs by deploying a sales force to penetrate men’s health and wellness clinics across the US. The newly developed clinic prescribing system enables practitioners to prescribe MangoRx products, including the recently launched 'PRIME', by MangoRx, powered by Kyzatrex®️.

Insights

Market Research Analyst

The launch of Mangoceuticals' direct-to-clinics sales division represents a strategic pivot likely to influence the company's market positioning and financial performance. By integrating a prescribing system that enables physicians to directly prescribe MangoRx products, the company is effectively streamlining the point of care to point of sale process. This could potentially increase product uptake due to the convenience it offers to both doctors and patients. The direct sales approach may also enhance customer loyalty and brand recognition within the men's health and wellness sector.

From a market research perspective, this initiative taps into a significant opportunity. By targeting men's health clinics and related facilities, MangoRx is accessing a customer base with a demonstrated need for their products. The reference to 6,000 to 7,000 ED prescriptions per provider per year underscores the substantial market demand. This direct engagement with healthcare providers could also provide a competitive edge over rivals who may rely more heavily on traditional digital marketing approaches.

However, the success of this strategy will hinge on the company's ability to effectively deploy its sales force and manage the associated costs. The long-term sustainability will depend on the balance between the increased revenue from direct sales and the operational costs of maintaining the sales division and the prescribing system.

Financial Analyst

MangoRx's strategic shift to a direct-to-clinics sales model is anticipated to have a notable impact on its financials, particularly in terms of recurring revenues and customer acquisition costs (CACs). By bypassing traditional digital marketing channels, the company may see a reduction in CACs, which are often a significant expense for telemedicine and pharmaceutical companies. Additionally, the mention of a $199 monthly subscription rate for 'PRIME' indicates a recurring revenue model that could enhance financial stability and predictability.

Investors should monitor the company's quarterly financials for changes in revenue growth, profit margins and CACs as indicators of the initiative's effectiveness. It is also important to consider the scalability of the sales force and the potential need for increased investment in personnel and training to support the expansion. The onboarding of the first clinic in Dallas serves as a proof of concept and the rate at which additional clinics are onboarded will be a critical metric to watch.

While the potential for exponential growth is highlighted by the CEO, it is vital to approach these projections with caution. The actual market penetration and customer retention rates will determine the long-term financial impact of this initiative.

Medical Industry Analyst

The introduction of a custom-built prescribing system by MangoRx is a significant development within the men's health and wellness pharmaceutical industry. By enabling practitioners to directly prescribe products such as the 'Mango' ED drug and 'PRIME' TRT, MangoRx is leveraging technology to create a more integrated healthcare experience. This approach could potentially improve patient adherence to medication regimens and follow-up care, which are critical factors in treatment outcomes.

It is also noteworthy that MangoRx has chosen to partner with Kyzatrex®️ for its 'PRIME' TRT product. The collaboration with an FDA-approved testosterone replacement therapy could lend credibility and trust to MangoRx's product line. As the industry continues to evolve, the ability to quickly adapt and integrate innovative solutions like these will be crucial for companies looking to maintain a competitive edge.

The impact on the broader industry will likely be observed in how competitors respond to MangoRx's direct-to-clinics model. If successful, this could prompt a shift in how pharmaceutical products are marketed and distributed, particularly within specialty therapeutic areas.

Newly developed clinic prescribing system will allow Doctors to prescribe MangoRx products from within practices and clinics

Dallas, Texas, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products via a secure telemedicine platform, including its uniquely formulated erectile dysfunction (ED) drug (‘Mango’), its hair growth product (‘GROW’), and its FDA approved oral testosterone replacement therapy (TRT), ‘PRIME’, by MangoRx, powered by Kyzatrex^®️, is excited to announce that it has officially launched its direct-to-clinics sales division offering doctors and medical practitioners the ability to prescribe MangoRx products to their patients directly from their offices, clinics and brick and mortar locations. The Company also reports that it has successfully onboarded its first medical health and wellness clinic based in Dallas, TX last week.

The Company believes that this direct-to-clinics initiative will assist in fueling a greater amount of recurring revenues while at the same time reducing customer acquisition costs (CACs) associated with traditional digital marketing strategies. The first of its kind within MangoRx’s direct competitor group, the Company will be deploying a boots-on-the-ground sales force with a mission to penetrate existing brick and mortar men’s health and wellness clinics across the United States, including but not limited to Med Spas, Low Testosterone clinics, and specialty doctors’ offices.

Jonathan Arango, MangoRx’s Co-Founder and President noted, “we are very excited for the launch of this direct-to-clinics initiative as this has been a part of our business plan and in the works since the 4^th quarter of 2023. Since we have launched our Mango ED products, many doctors have approached us asking how they could prescribe Mango to their existing patients. This led us to design our newly custom-built prescribing system that allows for the practitioner to prescribe MangoRx products – including our newly launched ‘PRIME’, by MangoRx, powered by Kyzatrex^®️ – while at the same time acquiring a new MangoRx customer within our ecosystem.”

MangoRx transactions are currently being initiated by consumers seeking MangoRx’s products. This newly developed prescribing system will now allow for prescribing doctors and medical practitioners to initiate the transaction for the sale of MangoRx’s products. The Company will be activating a website where providers and clinics can visit to complete the onboarding process to qualify as a MangoRx preferred provider.

Jacob Cohen, MangoRx’s Co-Founder and CEO noted, “our initial research has shown that some of these providers prescribe as many as 6,000 to 7,000 ED prescriptions per year from within their offices or clinics. This amount, compounded with the opportunity for them to also prescribe ‘PRIME’, by MangoRx, powered by Kyzatrex^®️, presents an exponential growth opportunity especially given PRIME’s $199 monthly subscription rate. We are confident that this new initiative will fuel our revenue growth and have a further impact on making MangoRx a household name.”

About MangoRx

MangoRx is focused on developing a variety of men's health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men's wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth and hormone replacement therapies. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep.

To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx.

Cautionary Note Regarding Forward-Looking Statements

Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 ("forward-looking statements"). These forward-looking statements represent the Company's current expectations or beliefs concerning future events and can generally be identified using statements that include words such as "estimate," "expects," "project," "believe," "anticipate," "intend," "plan," "foresee," "forecast," "likely," "will," "target" or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company's control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, including, but not limited to; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our ED product which have not been, and will not be, approved by the U.S. Food and Drug Administration ("FDA") and have not had the benefit of the FDA's clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our planned products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act ("FFDCA Act") provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen and President, Jonathan Arango, combined have majority voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace, and the fact that the majority of our shareholders paid less for their shares than the public offering price of our common stock in our recent initial public offering; the fact that we have a significant number of outstanding warrants to purchase shares of common stock at $1.00 per share, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended; our ability to build and maintain our brand; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our ED product; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our Mango ED product, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of high inflation, increasing interest rates and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company's products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties.

More information on potential factors that could affect the Company's financial results is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's filings with the SEC, including the Company’s Quarterly Report on Form 10-Q for the Quarter ended September 30, 2023. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company's future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Follow Mangoceuticals and MangoRx on social media:
https://www.instagram.com/mango.rx
https://twitter.com/Mangoceuticals
https://www.facebook.com/MangoRxOfficial

FOR PUBLIC RELATIONS
Lucky Break Public Relations
Sahra Simpson
Sahra@luckybreakpr.com
(323) 602-0091 ext. 704

FOR INVESTOR RELATIONS
Mangoceuticals Investor Relations
Email: investors@mangorx.com

MEDIA CONTACT
PHOENIX MGMT Marketing & Consulting
info@phoenix-mediamarketing.com

SOURCE: Mangoceuticals Inc.

FAQ

What is the purpose of Mangoceuticals, Inc.'s direct-to-clinics sales division launch?

Mangoceuticals, Inc. launched the direct-to-clinics sales division to allow doctors to prescribe MangoRx products directly from their offices, aiming to increase recurring revenues and reduce customer acquisition costs.

What products can doctors prescribe using the newly developed clinic prescribing system?

Doctors can prescribe MangoRx products, including the erectile dysfunction (ED) drug 'Mango', the hair growth product 'GROW', and the FDA approved oral testosterone replacement therapy 'PRIME', by MangoRx, powered by Kyzatrex®️ using the clinic prescribing system.

What is the significance of the direct-to-clinics initiative for Mangoceuticals, Inc.?

The direct-to-clinics initiative is expected to fuel revenue growth for Mangoceuticals, Inc. by enabling doctors to prescribe MangoRx products, including 'PRIME', by MangoRx, powered by Kyzatrex®️, leading to an increase in sales and making MangoRx a household name.

How can providers and clinics qualify as MangoRx preferred providers?

Providers and clinics can visit the MangoRx website to complete the onboarding process and qualify as MangoRx preferred providers to prescribe MangoRx products using the newly developed clinic prescribing system.

What growth opportunities does Mangoceuticals, Inc. anticipate with the direct-to-clinics sales division?

Mangoceuticals, Inc. anticipates exponential growth opportunities with the direct-to-clinics sales division, especially with the potential for doctors to prescribe 'PRIME', by MangoRx, powered by Kyzatrex®️, alongside other products, leading to increased revenue.